ReviewMolecular neurobiology2025
Quaking Protein in Myelin Maintenance and Regeneration in the Central Nervous System.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Synthesized by oligodendrocytes (OLGs) in the central nervous system (CNS), the myelin sheath is a multilamellar structure that enables the rapid transmission of action potentials and provides metabolic support to the axons it surrounds. In multiple sclerosis (MS), a chronic neurological disorder, the myelin membrane becomes the target of immune-mediated attacks. These attacks trigger the release of inflammatory cytokines and activate microglia (MG) and astrocytes, leading to severe demyelination and neurodegeneration. Quaking (QKI) is a multifunctional RNA-binding protein that plays a critical role in CNS myelination by regulating RNA metabolism and lipid homeostasis in glial cells. Through its major isoforms-QKI-5, QKI-6, and QKI-7-QKI orchestrates essential post-transcriptional processes in OLGs, including splicing, stability, nuclear export, and local translation of key myelin transcripts. QKI deficiency alters the expression of numerous genes involved in axonal ensheathment and myelination pathways, such as MBP, PLP1, MAG, and Nfasc155. QKI also modulates cholesterol and fatty acid biosynthesis by acting as a transcriptional coactivator, ensuring the proper lipid composition of the myelin sheath. In MG, QKI regulates phagosome maturation and the expression of inflammatory genes, thus promoting efficient clearance of myelin debris and fostering a permissive environment for remyelination. Reduced QKI expression has been documented in MS and its experimental models. In this context, this review summarizes current evidence positioning QKI as a central regulator of myelin maintenance and regeneration and highlights its potential as a therapeutic target for demyelinating diseases.
Indexed as
Identifiers
40555892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.